Clinical trial NCT04385849: Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
Official title: Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: COVID-19
Lead sponsor: ImmunityBio, Inc.
Sponsor class: INDUSTRY
First posted: 2020-05-13
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.


Eligibility criteria: Inclusion Criteria

1. Age ≥ 18 years old.
2. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
3. Has laboratory-confirmed positive novel coronavirus (SARS-CoV-2) test, as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen \< 72 hours prior to enrollment, or meets the criteria to guide the evaluation and testing of patients under investigation (PUI) for COVID-19 (https://emergency.cdc.gov/han/2020/HAN00428.asp).
4. Has a confirmed NEW score of 0-5.
5. Has at least one of the following high-risk factors associated with a higher risk of COVID-19 progression:

   1. Age ≥ 60 years.
   2. Hypertension currently managed by at least 1 antihypertensive medication.
   3. Type 1 or 2 diabetes.
   4. Chronic obstructive pulmonary disease (COPD) diagnosed per medical history.
6. Adequate respiratory and heart function, evidenced by the following laboratory results:

   1. Respiratory rate (RR) \< 20 breaths per minute (bpm).
   2. Heart rate (HR) \< 90 beats per minute (bpm).
   3. Arterial oxygen saturation (SaO2) \> 93% on room air.
7. Agrees to the collection of nasopharyngeal (NP) swabs and venous blood per protocol.
8. Ability to participate in required study visits and participate in adequate follow-up, as required by this protocol.
9. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception while on study and for at least 1 month after the last dose of N-803. Non-sterile male subjects must agree to use a condom while on study and for up to 1 month after the last dose of N-803. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and abstinence.

Exclusion Criteria:

1. Shortness of breath or hypoxia defined by a ratio of partial pressure of arterial oxygen to the percentage of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg or signs of serious lower airway disease.
2. Signs or symptoms of acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS)/shock, or cardiac failure; or need for supplemental oxygen.
3. Inflammatory markers (C-reactive protein \[CRP\], lactate dehydrogenase \[LDH\], d-dimer, ferritin, and IL-6) \> 1.5 × upper limit of normal (ULN).
4. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
5. Pregnant and nursing women. A negative serum or urine pregnancy test during screening prior to the first dose must be documented before N-803 is administered to a female subject of child-bearing potential.

Primary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lynwood
country: United States
facility: St. Francis
state: California
Study officials:
References: